HDT Bio announced that it has received a grant of ~$1.8 million from the US Army Medical Research Acquisition Activity for development of the company's HDT-201 RNA-based nasal spray for the prevention and treatment of viral infections. The company said that the funding will support pre-clinical safety and potency studies, with clinical trials anticipated to begin in … [Read more...] about HDT Bio Gets $1.8 million for US Army for development of antiviral nasal spray
Business
Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans
Canadian biotech Ceapro announced the expansion of an existing collaboration with McMaster University for development of inhaled yeast beta glucans for the prevention and treatment of lung fibrosis caused by COVID-19. According to Ceapro, the team has already successfully created inhalable yeast beta glucan particles via PGX and now plans to optimize delivery and … [Read more...] about Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans
Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation
Harm Reduction Therapeutics announced that it has signed a commercial supply agreement for its RiVive (HRT001) intranasal naloxone after the FDA granted Fast Track designation to the nasal spray, which is in development as a low cost OTC product for the reversal of opioid overdose. HRT did not name the company it contracted with but said that RiVive would be … [Read more...] about Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation
Tonix gets US patent for the use of intranasal potentiated oxytocin for the treatment of migraine
According to Tonix Pharmaceuticals, the United States Patent and Trademark Office has issued the company US Patent 11,389,473,"Magnesium-Containing Oxytocin Formulations and Methods of Use," which includes claims related to the use of such formulations for the treatment of pain such as migraine headache. The anticipated expiration date for the patent is January 7, … [Read more...] about Tonix gets US patent for the use of intranasal potentiated oxytocin for the treatment of migraine
Atossa to refocus development of AT-H201 on the treatment of radiation-induced lung injury
Atossa Therapeutics said that it has completed the first three parts of a Phase 1/2a trial, which was announced in July 2021, but it will skip the remaining part. Part D had been expected to enroll hospitalized COVID-19 patients; however, the company said that it will instead shift development of the inhaled heparin / n-acetylcysteine therapy to the treatment of … [Read more...] about Atossa to refocus development of AT-H201 on the treatment of radiation-induced lung injury
ARS to merge with Silverback to support development and commercialization of Neffy epinephrine nasal spray
ARS Pharmaceuticals plans to merge with Silverback Therapeutics, the companies said, with the combined company focused on approval and launch of ARS's Neffy (ARS-1) epinephrine nasal spray for the treatment of allergic reactions. Shareholders of Silverback, whose pipeline consists of a therapy for the treatment of chronic hepatitis B in early development, will own a … [Read more...] about ARS to merge with Silverback to support development and commercialization of Neffy epinephrine nasal spray
SoftOx gets funding from European Defense Fund to develop inhalation solution as a military countermeasure
SoftOx Solutions has announced that the European Defense Fund has awarded a 3-year grant of approximately NOK 97 million (~€9.6 million) to the company's subsidiary SoftOx Defense Solutions (SDS) for development of an inhalation solution as a part of a project developing countermeasures against harm from chemical, biologic, radioactive, and nuclear (CBRN) substances. … [Read more...] about SoftOx gets funding from European Defense Fund to develop inhalation solution as a military countermeasure
PTAB rules in Liquidia’s favor, finds another Tyvaso patent’s claims are not patentable
According to Liquidia, the US Patent Trial and Appeal Board (PTAB) has found that none of the claims included in US Patent No. 10,716,793, covering Tyvaso inhaled treprostinil, are valid. The company said that the PTAB ruling would have to be upheld on appeal before it can affect a court ruling holding up final approval of Liquidia's NDA for … [Read more...] about PTAB rules in Liquidia’s favor, finds another Tyvaso patent’s claims are not patentable
Recipharm to develop two inhalation formulations for Transpire Bio
Florida-based startup Transpire Bio announced that it has signed an agreement with Recipharm for development of two inhaled candidates, TRB-1 and TRB-2, for the treatment of asthma and COPD. The company says that the two generic MDIs are "intended for advanced markets." Transpire CEO Xian-Ming Zeng said, "Our mission is to improve access to important, life-saving … [Read more...] about Recipharm to develop two inhalation formulations for Transpire Bio
VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany
German digital health company VisionHealth has announced that it will "cooperate on distribution of inhalation platform Kata" with Boehringer Ingelheim in Germany. The Kata app uses artificial intelligence and augmented reality technology in conjunction with the patient's smartphone camera to provide interactive inhaler use coaching. The company says that the app can … [Read more...] about VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany